The FDA has issued over 50 warning letters to telehealth companies and medical spas regarding the marketing of compounded GLP-1 obesity drugs. The letters target providers for making false or misleading claims, specifically implying that these compounded versions are identical to FDA-approved branded medications. This action is part of a broader Department of Health and Human Services initiative to regulate direct-to-consumer drug advertising.